Search results
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
Zacks via Yahoo Finance· 3 days agoPRME has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell &...
John J. York Opens Up About ‘General Hospital’ Return After Cancer Battle: ‘Had a Little Break’
Us Weekly via Yahoo News· 7 days agoABC/Craig Sjodin John J. York opened up about returning to General Hospital while battling two types...
Beginning of the End: Upcoming Deadlines, Resolution Updates in Mass Tort Litigation | New York Law...
Law.com· 4 days agoThe Boy Scouts of America (BSA) bankruptcy has a pivotal deadline this summer, which marks a...
Protein arginine methyltransferase 2 controls inflammatory signaling in acute myeloid leukemia -...
Nature· 4 days agoPRMT2 is a key regulator of inflammation in acute myeloid leukemia. PRMT2-deficient cells exhibit a pro-inflammatory profile associated with STAT3 activation.
General Hospital’s John J. York Opens Up About His Emotional Return — But Where In the World Has Mac...
SheKnows· 3 days agoGeneral Hospital's John J. York opens up about his return to Port Charles after his cancer battle,...
Treatment of Blood Cancers
Digital Journal· 6 days agoVancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 18, 2024) - Investorideas.com, a go-to investing platform covering biotech and medical technology stocks releases the ...
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Significant Growth in Short Interest
ETF DAILY NEWS· 6 days agoCullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) saw a significant growth in short interest in the month of May. As of May 31st, there was short interest totalling 4,340,000 shares ...
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Down to $18.88
ETF DAILY NEWS· 5 days agoCullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) shares gapped down prior to trading on Monday . Cullinan Therapeutics shares last traded at $18.56, with a volume of 60,955 shares ...
Keros Therapeutics (NASDAQ:KROS) Given “Buy” Rating at HC Wainwright
ETF DAILY NEWS· 6 days agoKeros Therapeutics (NASDAQ:KROS – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report issued on Tuesday, Benzinga reports. They currently ...
Keros Therapeutics (NASDAQ:KROS) Rating Reiterated by Truist Financial
ETF DAILY NEWS· 4 days agoKeros Therapeutics (NASDAQ:KROS – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at Truist Financial in a research report issued to clients and investors on Tuesday ...